Solid Tumor Targeting CAR-T Safety & Control Development Services

Molecular switches play important roles in CAR-T immunotherapy, enabling precise spatiotemporal control over T cell activity and significantly enhancing both the safety profile and therapeutic specificity of treatment. Creative Biolabs' Solid Tumor Targeting CAR-T Safety & Control Development Services offer comprehensive solutions for the design and construction of customized CAR-T cells integrated with diverse switch systems tailored to target solid tumor antigens with high precision. By leveraging cutting-edge molecular engineering and validated regulatory mechanisms, we ensure optimized controllability, reduced on-target/off-tumor toxicity, and mitigated risks of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

Introduction

Molecular switches, as a class of engineered components capable of remotely regulating CAR expression or function, have evolved into diverse types including receptor-regulating, cytotoxic, adapter-based, and costimulatory signaling switches. These systems enable precise spatiotemporal control over CAR-T activity through distinct mechanisms such as modulating CAR protein stability, inducing T cell apoptosis, mediating antigen recognition, or fine-tuning costimulatory signals. The integration of such switch systems with CAR-T technology allows for real-time, reversible activation or termination of CAR-T cell cytotoxicity in vivo via external stimuli.

Fig.1 Key switch categories for CAR regulation.¹

Solid Tumor Targeting CAR-T Safety & Control Development Services at Creative Biolabs

Creative Biolabs' Solid Tumor Targeting CAR-T Safety & Control Development Services integrates advanced ON/OFF switch systems and universal adapter platforms to enable real-time, dose-titratable control over T cell activity. Our solutions combine synthetic biology design with metabolic fitness engineering to enhance persistence and reduce toxicity, delivering optimized constructs, comprehensive functional data, and validated safety mechanisms to support researches and development.

Service Packages

Our service portfolio provides end-to-end solutions for developing controllable CAR-T therapies. We deliver custom CAR designs with integrated safety switches, modular platforms to combat antigen heterogeneity, and comprehensive data packages.

Our Service Process

Required Starting Materials:

• Target Antigen Sequences: scFv or ligand sequence that recognizes the tumor-associated antigen.
• Initial CAR Construct Design: Details on the current CAR backbone.
• T cell Source Material: Access to patient T cell source (if autologous) or reference T cell lines for in vitro functional testing.

Key Steps:

Final Deliverables:

• Optimized Gene Transfer Vector: The final, validated ON/OFF switch CAR-T gene vector ready for manufacturing transition.
• Comprehensive Safety Data Report: Detailed pharmacodynamics (PD) and pharmacokinetics (PK) data on the switch molecule and T cell control.

Key Advantages

• Integrated Control Platform: Our modular, end-to-end platform supports the entire safety architecture workflow, from customizable ON/OFF/Dual/Adapter switch design to functional validation, all within a single-source framework.
• Rapid Safety Intervention (OFF Switch): We implement and validate high-response suicide switch systems, including proprietary iCasp9 technology, delivering immediate pharmacological intervention to address acute toxicities such as CRS and neurotoxicity.
• Tunable Activity & Durability: Leveraging precision adapter switch systems, we enable dose-adjustable control over T cell activation to mitigate exhaustion and sustain long-term antitumor function in solid tumors.

FAQs

Why Choose Us?

Creative Biolabs integrates safety and controllability into the core design of next-generation solid tumor CAR-T therapies. Our platform combines dynamically regulated ON/OFF switches, a universal adapter CAR system for multi-antigen targeting, and metabolic reprogramming strategies that enhance T cell persistence. We deliver end-to-end solutions to overcome key translational challenges, from safety risks and T cell exhaustion to antigen escape, enabling robust and viable CAR-T products for solid tumors.

Customer Reviews

"The integration of Creative Biolabs' Solid Tumor Targeting CAR-T Safety & Control platform enabled precise mitigation of T cell–mediated toxicity in our studies. The iCasp9 OFF-switch delivered rapid and reliable safety control, a critical capability absent in previous constitutive CAR systems." Dr. J**es.

"Creative Biolabs' switch-engineered CAR-T platform markedly enhanced T cell durability within immunosuppressive tumor microenvironments. Through pulsatile dosing via the adapter switch system, we successfully attenuated chronic activation and exhaustion, achieving sustained functional persistence beyond earlier non-regulatable CAR designs." Prof. A**ton.

"Leveraging Creative Biolabs' integrated ON/OFF-switch CAR-T system substantially strengthened our preclinical safety profile. The platform generated compelling evidence of titratable activity control, directly addressing key regulatory expectations and facilitating the timely submission of our Phase I trial application." S**rah W.

How to Contact Us?

Our Solid Tumor-Targeting CAR-T Safety & Control Platform integrates dynamic regulation systems, including titratable ON-switch mechanisms and rapid-response OFF-switch safety controls, to effectively address dose-limiting toxicities and prevent T cell exhaustion.

Ready to enhance the safety and efficacy of your CAR-T pipeline and advance the future of solid tumor treatment?

Connect with our team to explore tailored strategies for your project.

Reference

1. Głowacki, Paweł, and Piotr Rieske. "Application and Design of Switches Used in CAR." Cells vol. 11,12 1910. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/cells11121910.